Abstract:Background: Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis (IVH) due to diminished or absent inhibition of the complement system because of deficient expression of cell-anchored complement regulating surface proteins. IVH leads to heterogeneous symptoms such as anemia, abdominal pain, dyspnea, fatigue and increased rates of thrombophilia. Inhibitors of the terminal Complement cascade can reverse IVH leading to a significant reduction of disease burden such as thrombembolic events and also mortality. Summary: Therapeutic inhibitors of the terminal complement cascade such as eculizumab or ravulizumab significantly improve overall survival through IVH-inhibition. However, not all patients experience complete disease control with normalization of hemoglobin levels and absolute reticulocyte counts (ARC) under terminal complement inhibition as a significant part of patients develop extravascular hemolysis (EVH). EVH can be clinically relevant causing persistent anemia and fatigue. New proximal complement inhibitors (CI) mainly targeting complement component C3 or factors of the amplification pathway such as pegcetacoplan, danicopan, and iptacopan became available and are meanwhile approved for marketing. Additional complement-inhibiting strategies are under clinical development. A switch from terminal to proximal CI in patients with significant EVH can achieve hemoglobin and ARC normalization and significant improvement in quality of life (QoL). Additional approvals of proximal CI agents for the treatment of hemolytic PNH in the first line are available for pegcetacoplan and iptacopan. So far, no evidence-based algorithm is available for decision-making in first-line treatment of which type of drug should be used for individual patients. Key messages: Terminal CIs in hemolytic PNH patients can block IVH and have led to a dramatically improved survival. Proximal CIs ameliorate anemia and improve QoL in patients with relevant EVH. However, more (real-world) data are needed to demonstrate long-term improvement in all patients with hemolytic PNH, especially those under first-line treatment with proximal CI.

Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

Iptacopan: First Approval

Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH)

Iptacopan Efficacy and Safety to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy

Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria

Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials

Peptide Inhibitors of C3 Activation As a Novel Strategy of Complement Inhibition for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

MDS-278 Substantial Increases in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size with Oral Iptacopan Monotherapy Confirms Control of Hemolysis in Complement Inhibitor-Naive PNH Patients

Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease

Biotechnological products for the treatment of complement system disorders including paroxysmal nocturnal hemoglobinuria: currently available and in development

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab

First Successful Treatment of a Patient with a Primary Immune Complex-Membranoproliferative Glomerulonephritis with Iptacopan: A Case Report

Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations

Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria